Everything tagged "drug manufacturers general" across the TickerSpark archives.
11 articles
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Gilead Sciences, Inc. (GILD) gains 2.6% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.
Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.
Amgen’s portfolio is shifting toward faster-growing products like Repatha, EVENITY, and TEZSPIRE, but leverage and biosimilar erosion keep the stock in Hold territory. MariTide is the key medium-term catalyst, while Prolia and XGEVA remain the biggest drag.
GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.
Novo Nordisk still pairs elite profitability with strong obesity growth, but U.S. pricing pressure is tempering the once-clean hypergrowth story. The Wegovy pill and broader cardiometabolic pipeline keep the long-term case intact.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Eli Lilly is still one of the strongest growth stories in large-cap pharma, powered by tirzepatide and an expanding cardiometabolic pipeline. The stock remains constructive, but valuation now demands continued execution rather than multiple expansion.
AstraZeneca combines durable large-cap biopharma scale with broad-based growth across oncology, rare disease, and respiratory. The report rates AZN a Buy, with valuation the main debate and fair value anchored at $215.
AbbVie is showing that its post-Humira rebuild is real, with Skyrizi and Rinvoq driving strong growth and full-year guidance moving higher. Heavy debt and a negative equity position remain the main risks, but cash flow and earnings power still look compelling.
Merck combines elite cash generation with a growing pipeline, but KEYTRUDA still drives nearly half of sales. The stock looks like a quality compounder as new launches help reduce concentration risk.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime